Avadel Pharmaceuticals to Host Commercial Day on June 29 for LUMRYZ™ (sodium oxybate) extended release for oral solution, CIIIGlobeNewsWire • 06/22/23
Avadel Pharmaceuticals Sponsors the Academy of Sleep Medicine Foundation's 2023 Young Investigators Research ForumGlobeNewsWire • 06/14/23
Avadel Pharmaceuticals Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-at-Bedtime Oxybate Dosing for NarcolepsyGlobeNewsWire • 06/13/23
Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with NarcolepsyGlobeNewsWire • 06/05/23
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023GlobeNewsWire • 05/31/23
Avadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain BullishSeeking Alpha • 05/17/23
Avadel Pharmaceuticals' Strategic Moves To Conquer The Narcolepsy Market (Rating Upgrade)Seeking Alpha • 05/03/23
Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with NarcolepsyGlobeNewsWire • 05/01/23
Avadel: Sleeping Soundly, Why We're Giving A 'Buy' Rating Ahead Of Lumryz LaunchSeeking Alpha • 04/19/23
Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare ConferenceGlobeNewsWire • 04/10/23
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/30/23
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30GlobeNewsWire • 03/30/23
Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred SharesGlobeNewsWire • 03/30/23
Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred SharesGlobeNewsWire • 03/29/23
Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 MillionGlobeNewsWire • 03/29/23
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval DecisionGlobeNewsWire • 03/22/23
Avadel Pharmaceuticals: Real-World Data Supports Market Opportunity For LumryzSeeking Alpha • 03/12/23
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/08/23
Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly OxybatesGlobeNewsWire • 01/24/23
Avadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA's Orange BookGlobeNewsWire • 11/18/22